“New Era for Transplants”: Roswell Park Reports Increased Survival Outcomes One Year Following Allogeneic Transplant
ASCO26: Sara Tolaney, MD, MPH, ASCENT-03
ASCO26: Alicia Morgans, MD, MPH, ARACOG
ASCO26: Atish Choudhury, MD, PhD, A-DREAM/Alliance A032101
ASCO26: Sara Tolaney, MD, MPH, ASCENT-04
2026 ASCO Prostate Cancer Highlights
Updates in Transplant Oncology
2025 ATA Management Guidelines for Adult Patients with Differentiated Thyroid Cancer: Updates from the Endocrinology Perspective
Updates in Breast Cancer Surgery
Low-Dose Radiation Therapy for Arthritis
Treatment Guideline: First-Line Treatment for Metastatic Triple-Negative Breast Cancer (TNBC)
Turning Point focused on Women's Cancers
Treatment Guideline: Vaginal Estrogen in Patients with History of Breast Cancer
UCI Health Chao Family Comprehensive Cancer Center Annual Report 2025
Advancing Oncology Care
Treatment Guideline: Inavolisib, Palbociclib, and Fulvestrant for Hormone Receptor-Positive/HER2-negative Metastatic Breast Cancer
Dana-Farber Research Supports FDA Approval of New First-Line Therapy for Metastatic Triple-Negative Breast Cancer
Two Dana-Farber Hematologists Receive Top Honors From the American Society of Hematology
Dana-Farber Researcher Selected to Join the Pew Scholars Program
Fixed-Duration Triplet Therapy Demonstrates Efficacy for Patients with Relapsed/Refractory CLL
ImmunoPRISM Trial Shows Teclistamab Improves Depth of Response and Progression-Free Survival in High-Risk Smoldering Multiple Myeloma
Dana-Farber Research Supports FDA Approval of Pembrolizumab-Belzutifan Combination for Higher-Risk Clear Cell Kidney Cancer After Surgery
Cancer
Cardiology
Gastroenterology
Neurology
OBGYN
Orthopedics
Pediatrics
BroadcastMed News
Dermatology
Diabetes & Endocrinology
Infectious Diseases
Ophthalmology
Optometry
Otolaryngology
Pulmonology
Surgery
Urology
About
Solutions
Resources
Contact
person Sign In / Create Account
